NAD+ Injections vs NR and NMN Precursors Explained

Most people who spend money on NAD+ injections believe they are delivering NAD+ directly to their cells, and that the injection is more powerful than a pill because it skips digestion and goes straight into the bloodstream. The first part of that is true. The second part is where the logic breaks down.

To understand why, you need a map of how NAD+ actually works in the body, because without that map, the argument for injections sounds perfectly reasonable.

NAD+, which stands for nicotinamide adenine dinucleotide, is a molecule your cells use as a kind of electron shuttle, picking up and dropping off charged particles to power the energy production happening inside your mitochondria. Every cell in your body needs it constantly, and your total NAD+ supply turns over multiple times per day, meaning your body is continuously breaking it down and rebuilding it. The problem is that NAD+ is a large molecule, and large molecules cannot pass through cell membranes the way small ones can. The membrane is a selective barrier, and NAD+ does not have a direct transport mechanism that lets it cross intact into the interior of the cell where it is actually needed.

This is where the injection story gets complicated.

When you inject NAD+ into your bloodstream, the molecule circulates. But to get inside a cell and reach the mitochondria where it will be used, it cannot enter as NAD+. Instead, it gets broken down outside the cell into smaller components, specifically into something called nicotinamide, which is a simpler building block that cells can actually absorb. Once inside, the cell reconstructs NAD+ from that raw material through a series of enzymatic steps. The molecule you paid to inject was disassembled before it was used. What your cell actually worked with was the breakdown product, not the original compound.

This is not a flaw in your biology. It is the system working correctly. Cells maintain tight control over what enters them, and they have sophisticated machinery for building NAD+ internally from precursors. The same machinery runs whether the precursor came from an injection, a supplement, or food.

So when someone takes nicotinamide riboside, which is something called NR, a naturally occurring NAD+ precursor that cells can absorb directly and convert into NAD+, the end result inside the cell is functionally the same as what happens after an NAD+ injection. The NR skips the breakdown step because it is already the smaller component that the cell can work with. NMN, which stands for nicotinamide mononucleotide and is a slightly more downstream precursor than NR, works through a similar logic, though research into exactly how NMN enters cells is still being refined. Some evidence suggests it may be converted to NR before entering certain cell types, which would make the two precursors more similar in mechanism than their marketing suggests.

The clinical research on oral NR is more developed than for NMN. A study looking at NR supplementation found meaningful increases in blood NAD+ levels within two weeks at doses around 1,000 mg per day. Other work has shown that these increases translate to measurable changes in NAD+ levels in specific tissues, not just the bloodstream. NMN studies show similar directional results, though the dose ranging work is less mature and the long term data is thinner.

NAD+ injections do produce a rapid spike in circulating NAD+ levels, which is detectable in blood within hours. Some people report feeling something acutely from the injection, sometimes described as a flush or a surge of energy, and that experience is real. But the downstream cellular outcome, how much NAD+ your cells actually end up with after the breakdown and rebuild cycle, appears to be roughly equivalent to what you get from consistent oral precursor use. The injection front loads the process dramatically but does not appear to bypass the fundamental biology.

There is one area where the injection argument has more merit, and that is absorption variability. Some people have digestive issues or conditions that impair how well they absorb supplements through the gut. In those cases, injecting a precursor compound or even NAD+ itself might ensure delivery in a way that oral supplementation cannot. But for most people with normal gut function, the oral route gets the precursors into circulation efficiently enough that the injection provides no meaningful advantage.

The practical takeaway is simple. If you believe NAD+ precursors are worth supplementing, which the evidence for is promising but not yet conclusive at the level of hard clinical outcomes in healthy adults, then NR at roughly $1.50 per day or NMN at roughly $2 per day gets you to the same cellular destination as a significantly more expensive injection. The injection is not stronger. It is just faster to circulate, and that speed does not appear to change what happens once the biology takes over.

The deeper point here is about understanding what you are actually buying when you pay a premium for any supplement delivery method. Injections feel more medical, more direct, more potent. And in some contexts, like certain medications that genuinely cannot survive the digestive process, that premium is earned. But NAD+ injections are charging you for directness that the biology immediately undoes. Your cells do not care how the precursor arrived. They disassemble it all the same, carry the pieces through the membrane, and build what they need on the other side.

The Lego analogy is actually the most accurate thing you can say about it. The finished set gets taken apart at the door, and the pieces get reassembled inside. Paying more to ship the finished set does not change what the workers inside are putting together.

---

References

1. Chornyi S, IJlst L, van Roermund CWT et al.. Peroxisomal Metabolite and Cofactor Transport in Humans. Front Cell Dev Biol. 2020. Source
2. Wang Q, Zuurbier CJ, Huhn R et al.. Pharmacological Cardioprotection against Ischemia Reperfusion Injury-The Search for a Clinical Effective Therapy. Cells. 2023. Source
3. Smith KLM, Pasdois P, Pires M et al.. Fetal programming of the cardiac mitochondrial permeability transition pore in male offspring from hypoxic pregnancies. Redox Biol. 2026. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness